Table 1.
Summary of completed and ongoing clinical trials of anti- human epidermal growth factor receptor 2 agents in metastatic colorectal cancer
| Study | Phase | Treatment | Number of patients | Patient population | RR | mPFS | mOS |
| Rubinson[39] | I/II | Cetuximab + pertuzumab | 7 | Chemo- and cetuximab-refractory | 14% | 2.1 mo | 3.7 mo |
| Sartore-Bianchi (HERACLES)[40] | II | Trastuzumab + lapatinib | 27 | Chemo- and cetuximab/panitumumab-refractory | 30% | 21 wk | 46 wk |
| Hainsworth (MyPathway)[44] | II | Trastuzumab + pertuzumab | 34 | Chemo-refractory | 35% | NR | NR |
| Siena (HERACLES-RESCUE)[42] | II | Trastuzumab-emtansine | Recruiting | Chemo- and cetuximab/panitumumab and trastuzumab plus lapatinib-refractory | |||
| NCT03457896 | II | Neratinib + trastuzumab or cetuximab | Recruiting | Cetuximab and/or chemo-refractory | |||
| MOUNTAINEER[45] | II | Tucatinib + trastuzumab | Recruiting | Chemo- and bevacizumab-refractory |
RR: Response rate; mPFS: Median progression-free survival; mOS; Median overall survival; Chemo: Chemotherapy; NR: Not reported.